

Published in final edited form as:

Nature. 2017 April 27; 544(7651): 446–451. doi:10.1038/nature22064.

Structure and allosteric inhibition of excitatory amino acid transporter 1

Juan C. Canul-Tec^{#1,4}, Reda Assal^{#1,4}, Erica Cirri^{1,4}, Pierre Legrand², Sébastien Brier^{3,4}, Julia Chamot-Rooke^{3,4}, and Nicolas Reyes^{1,4,*}

¹Molecular Mechanisms of Membrane Transport Laboratory, Institut Pasteur, 25–28 rue du Docteur Roux, 75015 Paris, France

²Synchrotron SOLEIL, L'Orme des Merisiers, 91192 Gif-sur-Yvette, France

³Structural Mass Spectrometry and Proteomics Unit, Institut Pasteur, 25–28 rue du Docteur Roux, 75015 Paris, France

⁴UMR 3528, CNRS, Institut Pasteur, 25–28 rue du Docteur Roux, 75015 Paris, France

These authors contributed equally to this work.

Abstract

Human members of the solute carrier 1 (SLC1) family of transporters take up excitatory neurotransmitters in the brain and amino acids in peripheral organs. Dysregulation of their functions is associated to neurodegenerative disorders and cancer. Here we present the first crystal structures of a thermostabilized human SLC1 transporter, the excitatory amino acid transporter 1 (EAAT1), with and without allosteric and competitive inhibitors bound. The structures show novel architectural features of the human transporters, including intra- and extracellular domains with potential roles in transport function, as well as regulation by lipids and post-translational modifications. The coordination of the inhibitor in the structures and the change in the transporter dynamics measured by hydrogen-deuterium exchange mass spectrometry, reveal an allosteric mechanism of inhibition, whereby the transporter is locked in the outward-facing states of the transport cycle. Our results provide unprecedented insights into the molecular mechanisms of function and pharmacology of human SLC1 transporters.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

*Correspondence and requests for materials should be addressed to N.R. (nreyes@pasteur.fr).

Author contribution

J.C.C.-T., and R.A. optimized and performed protein expression, purification and crystallization, and R.A. performed molecular biology; J.C.C.-T., R.A., and N.R. collected crystallographic data, and J.C.C.-T., P.L., and N.R. analyzed diffraction data and structures; E.C. and R.A. performed and analyzed uptake experiments; E.C. prepared protein samples for HDX-MS; S.B. collected and analyzed HDX-MS data with help from E.C.; All authors contributed to the experimental design of the project and manuscript preparation. N.R. conceived and supervised the project.

Author Information The authors declare no competing financial interests.

Data availability

Coordinates and structure factors for the EAAT1_{cryst}-UCPH101, EAAT1_{cryst}-UCPH101-TBOA_{TFB}, EAAT1_{cryst}-II-UCPH101, and EAAT1_{cryst}-II crystal structures have been deposited in the Protein Data Bank with accession codes 5LLM, 5MJU, 5LM4, 5LLU, respectively. All other data are available from the corresponding author upon reasonable request.

SLC1 transporters constitute a large family of ion-coupled transporters present in all kingdoms of life¹. There are seven human SLC1 transporters (Extended Data Fig. 1) that evolved to serve two specialized functions²: in the central nervous system, SLC1 excitatory amino acid transporters (EAAT1-5) take up the neurotransmitter glutamate into the cell. In peripheral organs, EAATs take up glutamate and aspartate, while SLC1 neutral amino acid transporters (ASCT1-2) exchange small amino acids between the extra- and intracellular compartments, contributing to the cellular solute homeostasis.

Glutamate is the most important excitatory transmitter in the mammalian brain and it has to be continuously pumped into the cytoplasm to allow for rounds of transmission and prevent cytotoxicity. This essential neurological function is done by EAAT1-5 expressed at the plasma membrane of astrocytes and neurons³. In particular, astroglial EAAT1 and EAAT2 orthologs are highly expressed in the hind- and forebrain, respectively, and are responsible for most of the glutamate uptake in the rodent brain⁴. EAATs are powerful molecular pumps capable of maintaining up to 10^4 -fold glutamate gradients by using energy stored in sodium, proton and potassium gradients⁵. Remarkably, their dysregulation has been associated with several neurological diseases, including amyotrophic lateral sclerosis⁶, ataxia^{7,8}, stroke⁹, depression¹⁰ and glioma¹¹, making them important drug targets.

ASCTs are structurally related to EAATs, and function as sodium-dependent neutral amino acid exchangers at the plasma membrane¹². Importantly, ASCT2 is up regulated in several forms of cancer, including melanoma¹³, lung¹⁴, prostate¹⁵ and breast cancer¹⁶, and it is a key drug target in cancer therapy.

Despite the need for small compounds that selectively and allosterically modulate SLC1 human transporters, most of their pharmacology is based on substrate-analogs that inhibit transport competitively^{17,18}. The only known selective allosteric modulators of SLC1 transporters are a series of non-competitive EAAT1-selective inhibitors, of which 2-Amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH₁₀₁) is the best studied^{19,20}. However, its mechanism of action is still poorly understood at the molecular level.

In structural terms, most our knowledge on the transport mechanism and pharmacology of SLC1 transporters comes from the prokaryotic homolog GltPh that has been crystallized in the main conformational states of the transport cycle, outward-²¹ and inward-facing states^{22,23}, as well as in complex with a non-selective and competitive inhibitor of the EAATs²⁴, DL-threo- β -benzyloxyaspartic acid (TBOA). However, the presence of amino acid insertions and deletions, as well as important differences in the transport function and pharmacology of GltPh, make this homolog a limited structural model to understand the molecular mechanism of the human SLC1 proteins.

Here we present 3.1-3.3 Å X-ray crystal structures of thermostable EAAT1 variants in complex with a substrate (L-aspartate), and the allosteric inhibitor UCPH₁₀₁. The structures, and supporting functional data, show new architectural features of the EAATs and ASCTs, and unravel the allosteric mechanism of UCPH₁₀₁-like inhibitors in atomic detail. Taken

together, these structural data can prove useful for the design of novel allosteric compounds with improved selectivity for both EAATs and ASCTs.

EAAT1 engineering and crystallization

Purified wild-type EAAT1 lacks transport activity upon reconstitution in synthetic liposomes (Fig. 1a), and was recalcitrant to crystallization. To obtain functional protein suitable for crystallographic studies, we engineered a thermostable EAAT1, called EAAT_{cryst} that shares an overall ~75% sequence identity with the wild type, and up to ~90% identity at the C-terminal core of the protein (Extended Data Fig. 1; Methods), where the transported substrate and coupled ions are expected to bind^{24–29}. Indeed, purified EAAT_{cryst} reconstituted in liposomes showed robust glutamate uptake that depends on opposite gradients of sodium and potassium ions across the bilayer (Fig. 1a and Extended Data Fig. 2a), and was inhibited by the EAAT1-selective compound UCPH₁₀₁ (IC₅₀ of 4.5±0.3 μM, Hill coefficient 0.92±0.07) (Fig. 1b). These data show that the transport mechanism and pharmacological selectivity are conserved in EAAT_{cryst}.

Notably, EAAT_{cryst} crystallized in the presence of UCPH₁₀₁, and we solved its inhibitor-bound structure (see Methods and Extended Data Table 1), but it was refractory to crystallization in the absence of UCPH₁₀₁. To overcome this, we introduced M231I and F235I mutations in the inhibitor-binding pocket (Extended Data Fig. 1), and solved the crystal structures of the so-called EAAT_{cryst-II} both in the presence and absence of the inhibitor (Extended Data Table 1). Purified EAAT_{cryst-II} also showed robust sodium- and potassium-dependent glutamate uptake, while the UCPH₁₀₁ IC₅₀ increased >30-fold (>131±38 μM, Hill coefficient 0.92±0.0; Fig. 1a,b), as expected due to the mutations in the inhibitor binding pocket (see below).

Domain organization

The structure of EAAT_{cryst} shows a symmetric homotrimer in a substrate- and UCPH₁₀₁-bound outward-facing conformation (Fig. 1c-e) with an overall GltPh-like fold^{21,22} (Extended Data Fig. 3). Each monomer is composed of two domains: a scaffold domain (ScaD), including transmembrane helices TM1-2 and TM4-5; and a transport domain (TranD), including TM3, TM6-8 and re-entrant helical loops 1-2 (HP1-2; Fig. 1f). The three ScaDs form a compact central structure with a propeller-like shape that ensures the trimeric form of the transporter and anchors it to the membrane (Extended Data Fig. 4). The three TranDs are more peripheral and localize between the blades of the propeller, making protein contacts exclusively with the ScaDs of their own monomer. The TranD-ScaD interface buries ~3,500 Å², including a conserved salt bridge between E256 and K364, through interactions of residues in the cytoplasmic parts of HP1, TM7, and TM3 (TranD), and TM2, TM4c, and TM5 (ScaD). On the extracellular side, additional contacts occurred between residues in HP2 and TM4 that are well conserved among human transporters (Extended Data Fig. 5).

Substrate and ion translocation in SLC1 transporters is thought to occur through large rigid-body movements of the TranD, relative to the static ScaD, that move the cargo in an

elevator-like fashion across the membrane^{22,30}. Thus, during the isomerization to the inward-facing state the TranD-ScaD interface changes drastically on the TranD side, and the novel features observed at this interface in EAAT1_{cryst} might influence the distinct TranD dynamics in human SLC1 proteins.

Transport domain

One of the most remarkable architectural features of the EAAT1_{cryst} TranD is in TM8, where there are deletions and insertions compared to prokaryotic homologs (Fig. 2 and Extended Data Fig. 3). In EAAT1_{cryst}, TM8 can be divided into extracellular (TM8a), transmembrane (TM8b), and cytoplasmic (TM8c) helices. The loop connecting TM8a and HP2 is six residues shorter in human SLC1 transporters, and brings their extracellular ends in close contact through hydrogen bonding and hydrophobic interactions (Fig. 2). HP2 is a dynamic element that controls the access of substrate and ions to their binding sites in the TranD^{24,31–33}, and its interactions with TM8b likely play an important role in determining HP2 movements. Consistently, single-cysteine mutations at positions along TM8a in EAAT1³⁴, and in a rodent EAAT2 ortholog³⁵ impaired glutamate transport, highlighting the significance of this extracellular region for function.

In TM8b, we found strong electron density for the substrate (L-aspartate) and one of the sodium ions (Na²⁺) in similar sites than in the structures of prokaryotic homologs^{24,29} (Fig. 2). Remarkably, the carboxylate group of D456 (TM8b), which coordinates the α -amino group of the substrate, is also at hydrogen bond distance with the hydroxyl group of S343 (HP1). Moreover, the guanidinium group of R457 (TM8b) engages in hydrogen bonding with HP1 residue G341, and possibly L340 and T342 that point their backbone carbonyl oxygen atoms towards TM8b. Residues S343 and R457 are well conserved in human SLC1 transporters, and substitutions at equivalent positions in EAAT1 (S363 and R477)³⁶, and EAAT3 (R445)³⁷ inactivate transport. In addition, the loss-of-function mutation R445W in EAAT3, equivalent to R457 in EAAT1_{cryst}, causes human dicarboxylic aminoaciduria³⁸. Overall, the functional studies and our structural data converge to suggest that interactions between conserved human residues at HP1 and TM8b are important to the correct folding and function of the transporters.

On the cytoplasmic side, TM8 extends beyond the membrane through a hydrophilic helix (TM8c) that makes contact with TM3 and TM7a (Fig. 2). EAAT2 deletion mutants in this region have a deleterious effect on transport function and membrane trafficking³⁹. Accordingly, an EAAT1 deletion in TM8c decreased glutamate uptake rate by ~2-fold (Extended Data Fig. 2b). Indeed, the functional data and the TM8c amino acid conservation among EAATs underscore the pivotal role of this novel structural motif in protein folding and transport kinetics.

Scaffold domain

The ScaD contains highly divergent regions, especially in TM4 (Extended Data Fig. 1), where EAAT1_{cryst} shows several unique architectural features. On the extracellular side, TM4a forms inter- and intra-monomeric contacts with TM2 and HP2, respectively.

Moreover, an amino acid insertion between TM4b and TM4c (TM4b-c loop) that appeared during the evolution of eukaryotic transporters protrudes into the central vestibule of the EAAT1_{cryst} trimer (Fig. 3a and Extended Data Fig. 4). The TM4b-c loop forms the center of the propeller, and makes extensive contacts within and between protomers. Although, we could not model the outermost residues in the TM4b-c loop (Y200-V210), they are expected to each out to the bulk solvent exposing an N-glycosylation site (N204). Notably, all human SLC1 transporters contain predicted N-glycosylation sites in the TM4b-c loop, suggesting a conserved role of this loop in the posttranslational processing of these proteins.

On the cytoplasmic side, TM1 bends and re-orient its N-terminal part (TM1a) nearly parallel to the membrane plane, which forms the tips of the propeller's blades (Fig. 1c and Fig. 3b). The position and amphipathic nature of TM1a suggests that it somehow interacts with the inner leaflet of the membrane. Consistently, in the hydrophobic crevice between TM1a and HP1a, we observe strong non-protein electron density that likely corresponds to bound detergent or lipid molecules (Fig. 3b). Interestingly, a second hydrophobic crevice between the extracellular part of TM4 and HP2, also shows strong non-protein electron density (Fig. 3a). A similar crevice was also noted in a substrate-bound structure of GltPh21.

Lipids strongly regulate SLC1 transport function^{40–44}, and those hydrophobic crevices at the interface between the TranD and ScaD, where large conformational changes occur during substrate translocation, might constitute sites for lipid regulation of transport function.

UCPH₁₀₁ binding site

The structure of EAAT1_{cryst} showed strong electron density for UCPH₁₀₁ in a hydrophobic pocket between TM3, TM7 and TM4c at the TranD-ScaD interface, where the compound extends the interface by $\sim 500 \text{ \AA}^2$ (Fig. 1d,e and Fig. 4a,b). The chromene skeleton, the parental group of the UCPH series of compounds, is buried deeply in the domains interface, and coordinated by a direct ring-stacking interaction with F369 (TM7a), as well as hydrophobic interactions with G120 (TM3), V373 (TM7a) and M231 (TM4c) (Fig. 4b). In addition, the amine group of UCPH₁₀₁ forms a hydrogen bond with the main-chain carbonyl of F369, while its carbonitrile group interacts with Y127 (TM3). The methoxy-phenyl and naphthalene groups appear partially facing the hydrocarbon core of the membrane. Yet, the former establishes hydrophobic interactions with V124 (TM3), V373 and M231, while the latter is mainly coordinated by F235 (TM4c). The majority of the above-mentioned residues are important for UCPH₁₀₁ transport inhibition of an EAAT1 rodent ortholog²⁰. Furthermore, the M231I-F235I double mutant (EAAT1_{cryst-II}) showed >30-fold increase in UCPH₁₀₁ IC₅₀ compared to EAAT1_{cryst} in proteo-liposomes (Fig. 1b). Hence, there is an excellent agreement between the crystallographic and functional data.

Several mechanistically-relevant observations can be made regarding the UCPH₁₀₁ binding pocket in EAAT1_{cryst}: i) it is over 15 Å away from the substrate and sodium binding sites, suggesting that UCPH₁₀₁ does not preclude extracellular substrate binding; ii) it faces the inner leaflet of the membrane, implying that UCPH₁₀₁ accesses its binding site from the lipidic, and not the aqueous phase, when applied extracellularly; iii) it is fully contained in a

single subunit, in agreement with the lack of cooperativity observed in proteo-liposome (Fig. 1b), and cell assays²⁰; iv) a comparison of the EAAT1-5 sequences suggests that the main determinants of UCPH₁₀₁ selectivity for EAAT1 are in TM4c, where M231 and F235 are the only coordinating residues that differ between EAAT1 and all other EAATs (Extended Data Fig. 1). Consistently, the double mutant EAAT1_{cryst-II} containing EAAT2 residues equivalent to M231-F235 shows a large IC₅₀ increase.

UCPH₁₀₁-unbound state

To better understand the conformational changes of the transporter induced by UCPH₁₀₁, we set out to determine the structure of the EAAT1_{cryst} UCPH₁₀₁-unbound state, but it was refractory to crystallization. Instead, we solved the structure of the EAAT1_{cryst-II} UCPH₁₀₁-unbound state and for comparison, the EAAT1_{cryst-II} UCPH₁₀₁-bound state, using an excess of the compound in the crystallization conditions (see Methods).

The EAAT1_{cryst-II} UCPH₁₀₁-bound state is nearly identical to that of the EAAT1_{cryst} with the exception of the I231 and I235 side chains, and a ~2 Å movement of UCPH₁₀₁ methoxy-phenyl and naphthalene groups away from them (Fig. 4c and Extended Data Fig. 6a). However, the EAAT1_{cryst-II} UCPH₁₀₁-unbound structure shows notable differences with bound state. First, there is no excess electron density for UCPH₁₀₁, and the side chain of F369 moves outward by as much as 1.9 Å, partly occupying the volume of the UCPH₁₀₁ chromene group (Fig. 4c). Second, there is a small rigid-body movement of the entire TranD that shifts by as much as 0.7 Å, compared to the UCPH₁₀₁-bound structures (Extended Data Fig. 6b). This conformational change shows the EAAT1_{cryst} TranD is able to move as rigid bodies relative to the ScaD, and highlights the importance of such movements for the function of the human transporters, as it has been shown for GltPh22,23.

The structural changes observed in the UCPH₁₀₁-unbound structure unambiguously demonstrate that the assigned binding pocket of UCPH₁₀₁ is correct, and that within the restricted environment of the crystal lattice, UCPH₁₀₁ induces both local and global conformational changes of the transporter that optimize its coordination in an outward-facing state.

Transport domain dynamics

The coordination of UCPH₁₀₁ in the crystal structures, wedged in the TranD-ScaD interface, as well as the effect of the M231I-F235I mutations on its potency strongly suggest that UCPH₁₀₁ inhibits transport by trapping the transporter in an outward-facing state. Consistently, the rigid-body movements of the TranD to isomerize the transporter into the inward-facing state would separate the coordinating residues in the TranD from those in the ScaD, and disrupt the UCPH₁₀₁ coordination. Hence, under equilibrium conditions where the transporters are sampling outward- and inward-facing states, the expected effect of UCPH₁₀₁ binding is to shift the equilibrium in favor of the outward-facing state.

To gain insights into the effects of UCPH₁₀₁ binding to the transporters at equilibrium, we probed the detergent solubilized EAAT1_{cryst} by hydrogen-deuterium exchange mass spectrometry (HDX-MS). HDX-MS measures the rate of exchange of backbone amide

hydrogen atoms that depends on solvent accessibility and hydrogen bonding, and provides valuable information on the dynamics and conformational changes of proteins^{45,46}.

We compared the HDX behavior of the EAAT1_{cryst} in the presence and absence of UCPH₁₀₁. Overall, the deuterium uptake pattern of EAAT1_{cryst} shows dynamic structural elements in both the TranD and ScaD (Extended Data Fig. 7-8), and reveals the unstructured and solvent-exposed nature of several regions that were not resolved in the crystal structures, including the TM3-TM4a (peptide 153-173) and TM4b-c (peptide 200-208) loops, as well as the N- (peptide 1-28) and C-termini (peptides 490-522) (Extended Data Fig. 9).

Binding of UCPH₁₀₁ significantly decreased deuterium uptake in several areas of the TranD including its binding pocket (residues 112-123 and 370-374), and the surrounding area (residues 354-369), while it left the uptake in the ScaD unchanged (Fig. 5a). It also decreased deuterium uptake in distant residues (336-349 and 420-430) at the tips of HP1 and HP2 involved in substrate coordination and occlusion, suggesting that UCPH₁₀₁ induces conformational changes in the transporter upon binding. To gain insights into the nature of those conformational changes, we first compared the TranD areas in which UCPH₁₀₁ decreased uptake with those buried at the interface with ScaD in the EAAT1_{cryst} structure, and found that they correlate remarkably well (Fig. 5a-c). Second, we built a model of the EAAT1_{cryst} inward-facing state, based on a recently solved structure of GltPh23, to assess the changes in solvent accessibility in a possible transition between inward- and outward-facing states (Fig. 5c,d). Indeed, the comparison between the structure and the model shows that the UCPH₁₀₁-modified areas detected by HDX-MS transit as rigid bodies from being solvent-exposed, in the inward-facing state, to buried at the TranD-ScaD interface, in the outward-facing state. Such conformational change is expected to decrease the dynamics of alpha helices and/or the solvent accessibility of the loops in the UCPH₁₀₁-modified areas and thus, is consistent with the observed decrease in deuterium uptake. Overall, the HDX-MS and structural analysis support the stabilization of the outward-facing state, at the expense of the inward-facing state(s), induced by UCPH₁₀₁.

UCPH₁₀₁- and TBOA_{TFB}-bound state

The distant position of UCPH₁₀₁ from the substrate and HP2, a structural element that controls extracellular access to the substrate binding site²⁴, suggests that the UCPH₁₀₁-bound transporters could undergo the conformational changes required to exchange the substrate with the extracellular solution. To test this, we solved the crystal structure of EAAT1_{cryst} in complex with both UCPH₁₀₁ and (2*S*,3*S*)-3-[3-[4-(trifluoromethyl)benzoylamino]benzyloxy]aspartate (TBOA_{TFB}), a potent and non-selective TBOA derivative⁴⁷, at 3.7 Å resolution (Extended Data Table 1).

Overall, the UCPH₁₀₁-TBOA_{TFB}-bound structure is similar to that of the UCPH₁₀₁-bound state, with the exception of HP2 that adopts an “open” conformation and packs against the TM4b-c loop, disrupting the coordination of the Na²⁺ (Fig. 6a,b). These conformational changes resemble those previously observed in the structure of the GltPh-TBOA complex, and are in excellent agreement with the proposed competitive inhibitory mechanism of TBOA-like compounds²⁴.

In the substrate-binding site, we observed excess electron density for the bulky TBOA_{TFB} (Fig. 6c), but due to lack of resolution, we were not able to unambiguously orient the compound. Hence, we initially positioned the TBOA moiety of TBOA_{TFB} using the TBOA-bound GltPh structure as a guide. After crystallographic refinement, the additional benzoylamino and trifluoromethyl groups of TBOA_{TFB} in EAAT1_{cryst} localized in a hydrophobic cavity mainly formed by residues in HP1b and TM7a, and possibly by residues in TM2 and TM4c, likely explaining the observed ~1500-fold increase in EAAT1 inhibitory potency over TBOA47.

Indeed, in the TBOA_{TFB}-bound structure UCPH₁₀₁ is bound with an identical coordination than in the substrate-bound state. Therefore, the EAAT1_{cryst} structures show that UCPH₁₀₁ binding at its allosteric site does not preclude the movements of HP2 involved in substrate and sodium binding from the extracellular solution.

Inhibitory mechanisms of EAAT1

The structural and functional EAAT1_{cryst} data reveal new architectural features of human SLC1 transporters, and their first molecular mechanism of allosteric inhibition. UCPH₁₀₁ binding “glues” the TranD to the ScaD in the outward-facing states, and precludes substrate translocation, but not binding from the extracellular solution (Fig. 7). Non-conserved residues in the ScaD determined UCPH₁₀₁ selectivity for EAAT1. This inhibitory mechanism contrasts with that of substrate-analog inhibitors like TBOA. The binding pocket of TBOA-like compounds overlaps with the conserved substrate binding site²⁴, explaining their lack of selectivity among glutamate transporters and the inhibition of substrate binding observed on either side of the membrane^{48,49}.

The unique inhibitory mechanism of UCPH₁₀₁ makes it an extremely valuable pharmacological tool to study the conformational changes that EAAT1 undergoes upon substrate and ion binding. Remarkably, the UCPH₁₀₁ allosteric binding site highlights a cavity that can facilitate the design of selective compounds for other human SLC1 transporters, and possibly the long-sought positive modulators of glutamate uptake.

Methods

Construct optimization

We used fluorescence-detection size-exclusion chromatography (FSEC)⁵⁰ to screen solubilization conditions and EAAT1 variants fused to enhanced green fluorescent protein (eGFP). EAAT1 N-terminal fusions solubilized in dodecanoyl sucrose (DDS, Anatrace) were found to have good solubility and mono-dispersity by FSEC in clear lysates. However, EAAT1 loses its transport activity and chromatographic monodispersity upon purification. To increase its stability, we used consensus mutagenesis⁵¹, and screened EAAT1 variants with different consensus mutations in the predicted transmembrane helices by FSEC. The apparent melting temperature (*T*_m) of the most stable EAAT1 construct was >20 °C over that of the wild-type EAAT1, but the mutated transporter was still refractory to crystallization. We reasoned that the divergent extracellular region between TM3-4c could interfere with crystallization, and changed it for the equivalent region in ASCT2, the shortest

one among human SLC1 members (Extended Data Fig.1). In addition, we mutated the two predicted N-glycosylation sites of the transporter (N155T and N204T mutations) to further improve crystallizability.

Expression and purification

All constructs were introduced into pcDNA3.1(+) (Invitrogen) with N-terminal Strep-tag II affinity tag followed by eGFP and PreScission protease cleavage site, and expressed in HEK293F cells (ATCC, mycoplasma test negative) grown in Excell293 medium (Sigma) and supplemented with 4mM L-glutamine (Sigma) and 5µg/ml Phenol red (Sigma-Aldrich) to densities of 2.5×10^6 cells ml⁻¹. Cells were transiently transfected in Freestyle293 medium (Invitrogen) using poly-ethylenimine (PEI) (Polysciences) at a density of 2.5×10^6 cells ml⁻¹, diluted with an equivalent volume of Excell293 6 hours post-transfection, and treated with 2.2 mM valproic acid (Sigma) 12 hours after dilution of the cultures. Cells were collected at ~48 h post-transfection.

Initial screens of constructs and detergent solubilization buffers were done in small-scale (5-10 ml), and cells were collected, mechanically disrupted with a douncer and solubilized in 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl buffer supplemented with 1 mM L-asp, 1 mM EDTA, 1 mM Phenylmethylsulfonyl fluoride (PMSF), 1 mM Tris(2-carboxyethyl)phosphine (TCEP), 1:200 (v/v) dilution of mammalian protease inhibitor cocktail (Sigma), 10 % glycerol, 2% detergent and 0.4% cholesterol hemisuccinate (CHS) (Anatrace). After 1-hour incubation at 4 °C, clear lysates were obtained by ultracentrifugation (247,000 g for 45 min). A high-throughput auto-sampler was used to inject the lysates in a SRT SEC-500 column (Sepax Technologies) equilibrated in 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl buffer supplemented with 1 mM L-asp, 1 mM TCEP, 5 % glycerol, 3 x CMC detergent, and ~0.01% CHS, in line with fluorescence detection (Photon technology international) for FSEC analysis.

Large-scale expression was done in 2-4 l cultures with cells collected in 50 mM HEPES/Tris-base, pH 7.4, 50 mM NaCl buffer supplemented with 1 mM L-asp, 1 mM EDTA, 1 mM PMSF, 1 mM TCEP, and 1:200 (v/v) dilution of mammalian protease inhibitor cocktail (Sigma), and disrupted in an cell homogenizer (EmulsiFlex-C5, Avestin) after 3 runs at 15,000 Psi. The resulting homogenate was clarified by centrifugation (4,500 g, 0.5 h) and the crude membranes were collected by ultracentrifugation (186,000 g for 1.5 h). Membranes were washed once with the above-mentioned buffer and finally homogenized with a douncer in a buffer containing 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 1 mM EDTA, 1 mM TCEP, and 10% Glycerol, snap-frozen in liquid N₂ and stored at -80°C at 0.5 g of membranes ml⁻¹.

Membrane solubilization was done by thawing out and supplementing the membrane homogenate with 2% DDS, 0.4% CHS, and 25 µM UCPH₁₀₁ (Abcam). After 1-hour incubation, the insoluble material was removed by ultracentrifugation (186,000g for 1 h), and Strep-Tactin sepharose resin (GE Healthcare) was added to the supernatant and rotated for 2 h. Resin was washed with 25 column volumes of 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 1 mM TCEP, 5% Glycerol, 0.05% DDS, 0.01% CHS and 25

μM UCPH₁₀₁, and the protein was eluted with the same buffer supplemented with 2.5 mM D-desthiobiotin.

The eluted eGFP-transporter fusion was concentrated to 1-2 mg ml⁻¹ using 100-kDa cutoff membranes (Millipore), and digested with His-tagged PreScission protease overnight at 4 °C. The protease was removed by reverse Ni-NTA (Qiagen) affinity chromatography, and the flow through containing the transporter was concentrated to 500 μl , ultra-centrifuged (86,900 *g*, 20 min), and applied to a Superose 6 10/300 gel filtration column (GE Healthcare) equilibrated with 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 1 mM TCEP, 5% Glycerol, 0.25% decanoyl sucrose (DS, Sigma), 0.05% CHS and 100 μM UCPH₁₀₁. To obtain the UCPH₁₀₁ unbound structure, the protocol was identical, but the allosteric inhibitor was omitted from all buffers. To obtain the UCPH₁₀₁-TBOA_{TFB} bound structure, the protein sample was supplemented with 3 mM TBOA_{TFB} (Tocris) before the injection in the gel filtration column equilibrated with 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM TCEP, 5% Glycerol, 0.25% decanoyl sucrose (DS, Sigma), 0.05% CHS, 300 μM TBOA_{TFB} and 100 μM UCPH₁₀₁.

Protein samples after the solubilization step were kept on ice or at 4 °C at all times.

Crystallization and structure determination

Purified protein was concentrated to 3.5-4.0 mg ml⁻¹ and 1 mM UCPH₁₀₁ was added in experiments with the inhibitor-bound transporters. Initial vapor diffusion crystallization screens were done by mixing 300 nl of protein and reservoir solution in sitting drops, dispensed by a Mosquito robot (TTP labtech) in 96-well Greiner plates. The purified transporters form three-dimensional crystals in several conditions containing low molecular weight polyethylene glycols. The best-diffracting crystals were obtained after manual optimization using 1.6 μl hanging drops at 4 °C, obtained by mixing equal volumes of protein supplemented with 0.2% n-Octyl- β -D-glucopyranoside (BOG, Anatrace) and 0.04% CHS, and reservoir solutions containing 100 mM Tris, pH 8.2, 50 mM CaCl₂, 50 mM BaCl₂, and 28-30% PEG 400. Crystals appeared after 24-48 h and reached their maximum size after a week. Crystals were flash-frozen in liquid nitrogen before X-ray diffraction data collection without any further cryo protection.

X-ray diffraction data were collected at beamlines PROXIMA-1 at the SOLEIL synchrotron (St Aubin, France) and at beamlines at the European Synchrotron Radiation Facility (Grenoble, France). In general, 2-3 data sets from single crystals were collected, and indexed, integrated, scaled and merged using XDS package⁵². Due to the anisotropic nature of the diffraction data, the DEBYE and STARANISO programs were applied to scale it using the STARANISO server (<http://staraniso.globalphasing.org/>). The software performs an anisotropic cut-off of merged intensity data with a Bayesian estimation of the structure amplitudes, and applies an anisotropic correction to the data. Table 1 shows the refinement statistics for the full sets of reflections truncated at the best high-resolution along h, k or l axis, values given by AIMLESS⁵³, before the anisotropic corrections computed by the STARANISO software. The corrected anisotropic amplitudes were then used for molecular replacement in PHASER⁵⁴, using the scaffold and transport domains of GltPh (PDB code 2NWL) as independent search models. The initial electron density maps were clearly

interpretable, and the final model was obtained through rounds of manual building in COOT55 and refinement in Buster56, until reaching good crystallographic statistics and stereochemistry (Extended Data Table 1). The model contains one EAAT1_{cryst} monomer per asymmetric unit and most of the EAAT1_{cryst} polypeptide (residues 37-487), with the exception of some residues in the extracellular loops between TM3-4a, TM4b-4c, TM5-6 and TM7b-HP2a. Sequence assignment was aided by anomalous difference Fourier maps from diffraction data collected with low energy X-rays (1.77 Å) to highlight the sulfur atoms of methionine and cysteine residues (Extended Data Fig. 6c,d). EAAT1_{cryst-II}, as well as the EAAT1_{cryst} UCPH₁₀₁-TBOA_{TFB} bound structures were solved by the same approach above mentioned, but using the EAAT1_{cryst} TranD and ScaD as independent search models for molecular replacement.

The stereochemical properties of the final models were analyzed with the Molprobtity server (<http://molprobtity.biochem.duke.edu/>). At least 95% of the residues in all models are in the Ramachandran favored region. Protein interfaces were analyzed with the PISA server (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html). Structural alignments were done with Superpose in the CCP4 suite. All structural figures were prepared with PyMOL Molecular Graphics System, Schrodinger, LLC.

Radioactive substrate transport assays

Unilamellar liposomes were made at 9:1 molar ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids) and CHS, in a buffer containing 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl and 1 mM L-asp. The transporters were purified as described above, but excluding the reverse chromatography step after protease cleavage, and using a Superose 6 10/300 column equilibrated with 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 0.5 mM TCEP, 0.0632% DDS, 0.01264% CHS, and 5% glycerol.

To reconstitute the protein, liposomes were first mixed with DDS at a 1:2 (w/w) lipid-to-detergent ratio for 1 h, and then the purified transporters were added at a 1:40 (w/w) protein-to-lipid ratio. Detergent removal was done at 4° C using SM-2 biobeads (BioRad) at 100 mg ml⁻¹. The internal solution of the liposomes was exchanged using 10 freeze-thaw cycles in the appropriate buffer. After extrusion through 400-nm polycarbonate membranes (Avanti Polar Lipids), the proteoliposomes were concentrated by ultracentrifugation (150,000 g for 30 min at 4°C) and resuspended at 20 mg of lipids ml⁻¹, for immediate use.

Substrate transport was assayed at 37°C. The uptake reaction was initiated by diluting the proteo-liposomes 10-fold into a buffer containing 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 50 μM L-glutamate, and 5 μM [¹⁴C]-L-glutamate (PerkinElmer), and 2.5% glycerol. After 30 min, 200-μl aliquots were diluted 5-fold into ice-cold quench buffer (50 mM HEPES/Tris-base, pH 7.4, 200 mM ChCl, and 2.5% glycerol), followed by immediate filtration and wash on nitrocellulose 0.22-μm filters (Millipore). Radioactivity was quantified by liquid scintillation using a Tri-Carb 3110TR counter (PerkinElmer). For the UCPH₁₀₁ titrations, proteo-liposomes were both pre-incubated for 20 min at room temperature, and assayed in the presence of UCPH₁₀₁. Background radioactivity was estimated from protein-free liposomes, and subtracted from the uptake data. Data was fitted to a Hill equation of the form:

$$F = F_{\infty} + F_{\infty} / (1 + (IC_{50} / [UCPH_{101}])^n)$$

Where F_{∞} is the final level of inhibition, F_{∞} is the final amplitude of the UCPH₁₀₁ effect, and n is the Hill coefficient.

To titrate the rate of L-glutamate transport by EAAT1_{cryst}, proteo-liposomes were assayed in the presence of 0, 5, 50 or 200 μ M L-glutamate supplemented with 1, 5, 5, or 5 μ M [¹⁴C]-L-glutamate, respectively. At each substrate concentration, the initial rate of transport was calculated by a linear fit to 120 s and 180 s uptake measurements with origin fixed at zero. Background radioactivity was estimated from protein-free liposomes, and subtracted from the uptake data.

For the cell-based transport uptake, cells were collected 36 h post-transfection, and washed three times and resuspended at a density of 50×10^6 cells ml^{-1} in 11 mM HEPES/Tris-base, pH 7.4, 140 mM ChCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgCl₂, and 10 mM D-glucose, for immediate use. The uptake assay was performed similarly to the one described for the proteo-liposomes, but using a reaction buffer containing 11 mM HEPES/Tris-base, pH 7.4, 140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgCl₂, 10 mM D-glucose, 50 μ M L-glutamate, and 5 μ M [¹⁴C]-L-glutamate, and 0.8- μ m nitrocellulose filters. Background radioactivity was estimated from cells transfected with empty vector, and subtracted from the uptake data.

Hydrogen-deuterium exchange mass spectrometry


HDX-MS experiments were performed with transporters purified as described in the proteo-liposome section, and using a Superose 6 5/150 gel filtration column equilibrated with 50 mM HEPES/Tris-base, 200 mM NaCl, pH 7.4, 1 mM L-asp, 0.5 mM TCEP, 0.0632% DDS, 0.01264% CHS, and 5% glycerol.

The purified EAAT1_{cryst} was incubated in ice for 30 min with 2.2% DMSO at a monomer concentration of 5.2 μ M, in the presence and absence of 102 μ M UCPH₁₀₁, respectively. Prior to labeling, 10 μ L of the unbound and UCPH₁₀₁-bound EAAT1_{cryst} solution was equilibrated for 10 min at room temperature. Deuterium exchange was initiated by adding 40 μ L of D₂O buffer (50 mM HEPES, pD 7.3, 200 mM NaCl, 1 mM L-asp, 5% glycerol, 0.0632% DDS, 0.01264% CHS, 0.5 mM TCEP) supplemented or not with 101.2 μ M UCPH₁₀₁. Assuming that the K_D and IC_{50} values of UCPH₁₀₁ are similar, ~96% of the transporters would remain bound during deuterium labeling. Aliquots of 10.4 pmols of protein were removed at defined deuterium exchange time points (from 10 sec to 60 min) and quenched upon mixing with an ice-cold acidic solution (0.75% formic acid, 5% glycerol) to decrease the pH to 2.6. Quenched samples were immediately snap-frozen in liquid N₂ and stored at -80°C until analysis.

Prior to mass analysis, quenched samples were rapidly thawed and immediately injected into a cooled nanoACQUITY UPLC HDX system (Waters corp.) maintained at 0°C. 8.6-pmol protein samples were on-line digested for 2 min at 20 °C using an in-house packed immobilized pepsin cartridge (2.0 x 20 mm, 66 μ L bed volume). The resulting peptides were trapped and desalted onto a C18 Trap column (VanGuard BEH 1.7 μ m, 2.1 x 5 mm, Waters


corp.) at a flow rate of 100 $\mu\text{L}/\text{min}$ of 0.15% formic acid, and then separated in 10 min by a linear gradient of acetonitrile from 5 to 40% at 40 $\mu\text{L}/\text{min}$ using an ACQUITY UPLC™ BEH C18 analytical column (1.7 μm , 1 x 100 mm, Waters corp.). After each run, the pepsin cartridge was manually cleaned with two consecutive washes of 1% formic acid, 5% acetonitrile, 1.5 M guanidinium chloride, pH 2.5. Blank injections were performed between each run to confirm the absence of carry-over.

Mass spectra were acquired in resolution and positive mode on a Synapt G2-Si HDMS mass spectrometer (Waters corp.) equipped with a standard electrospray ionization source, as described previously⁵⁷. Peptides were identified from undeuterated protein samples acquired in MS^E mode by database searching in ProteinLynX Global Server 3.0 (Waters corp.). Each fragmentation spectrum was manually inspected for assignment validation. Deuterium uptake values were calculated for each peptide using DynamX 3.0 (Waters corp.). Only one unique charge state was considered per peptide and no adjustment was made for back-exchange. HDX-MS results are reported as relative deuterium uptake values expressed in mass unit or fractional exchange⁵⁷. A statistical analysis was performed with MEMHDX⁵⁸ using a False Discovery Rate of 1%.

Extended Data**Extended Data Figure 1. Alignment of human SLC1 transporters.**

Amino acid sequences of EAAT1-5, ASCT1-2 and EAAT1_{cryst} are compared. The boundaries of the α -helices (cylinders) in the TranD (orange) and the ScdA (teal) seen in the EAAT1_{cryst} structure are shown. In order to confer crystallizability, the region between TM3 and TM4c (arrows) from ASCT2 was transferred to a thermally stabilized EAAT1. To further improve crystal formation in the absence of UPCH₁₀₁, mutations M231I and F235I (circles) were introduced to generate EAAT1_{cryst-II}. These substitutions are found in EAAT2.


Other residues involved in UPCH₁₀₁ coordination are more conserved (triangles). Sequences were aligned with Jalview59.



Extended Data Figure 2. EAAT1_{cryst} and EAAT1 glutamate uptake.


a, Initial rates of L-glutamate uptake from purified EAAT1_{cryst} reconstituted in liposomes. The solid line is the fit of a Michaelis-Menten equation to the data with $K_M=21 \pm 10 \mu\text{M}$ and $V_{\text{max}}= 13 \pm 1 \text{ pmol } \mu\text{g}^{-1} \text{ protein min}^{-1}$. The graph is the mean of three independent experiments, and error bars represent s.e.m.. **b**, L-glutamate uptake was measured in

HEK293 cells expressing WT EAAT1 (black circles) and a truncated mutant beyond E501 (red symbols). The initial rate of uptake decreased by ~2-fold in the EAAT1 truncated mutant. Data were normalized to the asymptotic level of glutamate uptake based on a monoexponential function. The rates obtained from the fits were 0.16 ± 0.03 and 0.08 ± 0.03 min^{-1} for EAAT1 and the truncated mutant, respectively. The graphs are means of 4 independent experiments done in duplicates. Error bars represent the s.e.m..




Extended Data Figure 3. EAAT1_{cryst} and GltPh structural comparison.

a-b EAAT1_{cryst} aligns to a monomer of GltPh (PDB 2NWL) with α -carbon r.m.s.d. of 1.4 Å. The ScaDs (EAAT1_{cryst} teal, and GltPh purple, **a**), and TranDs (EAAT1_{cryst} orange and GltPh, purple, **b**) are shown separately for clarity of display.




Extended Data Figure 4. EAAT1_{cryst} trimeric interface.

a-b, Interface of three ScaDs of the EAAT1_{cryst} UCPH₁₀₁-bound structure viewed from the extracellular side (**a**) and from the membrane (**b**). The TranDs are not shown. The ScaD of one monomer (black) buries 3,000 Å² in the trimerization interface through extensive contacts with the two other subunits (teal and purple surfaces), including six intermolecular salt bridges (shown as green sticks for the monomer in black). The surface area in the other two monomers is colored in light pink. Only residues that contribute ≥ 10 Å² of buried surface area are highlighted.




Extended Data Figure 5. TranD-ScaD interface.

a-b, EAAT1_{crist} monomer viewed from the membrane (solid black line). Residues in the TranD (colored black) bury 1,760 Å² at the interface with the ScaD (**a**). This interface extends to the extracellular side of the transporter through interactions between HP2-TM4 (sticks and pseudo-transparent spheres) (**b**). **c**, Cytoplasmic view of the monomer displaying the salt bridge between TM7 and TM5.




Extended Data Figure 6. Superposition of EAAT1_{cryst} and EAAT1_{cryst-II} structures.

a-b, The transport domains of EAAT1_{cryst} (teal) and EAAT1_{cryst-II} (pink) UCPH₁₀₁-bound structures superimpose accurately after aligning their scaffold domains (**a**). The overall α -carbon r.m.s.d. was 0.3 Å. However, the same alignment done with EAAT1_{cryst-II} UCPH₁₀₁-bound and -unbound structures shows a small but global movement of the transport domain (**b**), with a small increase in the overall α -carbon r.m.s.d. of 0.1 Å. **c,d** Anomalous difference Fourier maps contoured at the 2.8σ (pink mesh), from data collected at low energy X-rays (1.77 Å), show the correct sequence registry in both the TranD (orange, **a**) and the ScaD (teal, **b**).




Extended Data Figure 7. Peptide coverage map of EAAT1_{cryst}.

A total of 111 peptides covering 76.3% of the EAAT1_{cryst} sequence were identified by data independent MS/MS acquisition after 2 min digestion with immobilized pepsin. Each bar below the EAAT1_{cryst} sequence corresponds to a unique peptide. The 57 peptides colored in blue were further selected for HDX-MS data extraction and analysis. The two additional N-terminal residues (*i.e.*, GP) that remain after protein purification are also shown. The transmembrane helices (TM) of the TranD (orange) and the ScaD (cyan) are indicated above the sequence.




Extended Data Figure 8. UCPH₁₀₁ effect on the local hydrogen exchange behavior of EAAT1_{cryst}

a, HDX profiles of EAAT1_{cryst} (see Methods) in the apo (upper panel) and UCPH₁₀₁-bound state (middle panel). The relative fractional uptake determined for each peptide and at each time point is plotted as a function of peptide position. The black to red lines correspond to data acquired from 10 sec up to 1h, respectively. **b**, The fractional uptake difference plot was generated by subtracting the deuterium uptake values in the UCPH₁₀₁-unbound from those in the bound state. Negative uptake difference indicates UCPH₁₀₁-induced decrease in amide hydrogen exchange. Each dot corresponds to an average of three independent HDX-MS experiments. The four regions (labeled 1 to 4) showing a statistically significant modification ($p < 0.01$) of deuterium uptake upon binding of UCPH₁₀₁ are highlighted in grey.



Extended Data Figure 9. HDX-MS results mapped on the crystal structure of ScaD and TranD of EAAT1_{cryst} in the unbound and UCPH₁₀₁-bound state.

The color code at the bottom shows the average relative fractional uptake measured in both domains after 10 sec (upper panel), 10 min (middle panel) and 1h (lower panel) labeling. Missing regions in the crystal structure are represented by dashed lines. Peptides showing a statistically significant ($p < 0.01$) modification of deuterium uptake upon UCPH₁₀₁ binding are labeled. Uncovered regions are colored in light blue.



Extended Data Figure 10.

Extended Data Table 1
Data collection and refinement statistics.

	EAAT1 _{cryst} UCPH ₁₀₁ bound	EAAT1 _{cryst-II} UCPH ₁₀₁ bound	EAAT1 _{cryst-II}	EAAT1 _{cryst} UCPH ₁₀₁ and TBOA _{TFB} bound
Data collection *				
Space group	<i>P</i> 6 ₃	<i>P</i> 6 ₃	<i>P</i> 6 ₃	<i>P</i> 6 ₃
Cell dimensions				
<i>a</i> = <i>b</i> , <i>c</i> (Å)	123.27, 89.87	123.11, 89.62	123.32, 89.57	124.33, 90.81
α = β , γ (°)	90.0, 120.0	90.0, 120.0	90.0, 120.0	90.0, 120.0
Wavelength	0.979	0.976	1.009	0.977
Resolution (Å)	34.50- 3.25 (3.34-3.25)	45.82- 3.1 (3.18-3.1)	45.87- 3.32 (3.41-3.32)	46.31- 3.71 (3.81-3.71)
Anisotropy direction [§]				
Resolution where CC _{1/2} > 0.3				
Overall (Å)	3.37	3.1	3.32	3.71
along h, k axis (Å)	3.75	3.68	3.85	4.35
along l axis (Å)	3.25	3.1	3.32	3.71
Measured reflections	333978 (24261)	290672 (21906)	326273 (21829)	141904 (11176)
Unique reflections	12338 (902)	14115 (1 032)	11556 (834)	8570 (628)
Completeness (%)	100 (100)	99.9 (99.9)	100 (100)	99.9 (100.0)
Mn (I) half-set correlation	0.99 (0.22)	1 (0.43)	0.99 (0.31)	0.99 (0.373)
<i>I</i> / σ (<i>I</i>)	11.7 (0.7)	15.8 (0.8)	13 (0.7)	12.1 (0.9)
<i>R</i> _{merge}	0.19 (6.8)	0.1 (6.71)	0.15 (8.03)	0.14 (3.71)

	EAAT1 _{cryst} UCPH ₁₀₁ bound	EAAT1 _{cryst-II} UCPH ₁₀₁ bound	EAAT1 _{cryst-II}	EAAT1 _{cryst} UCPH ₁₀₁ and TBOA _{TFB} bound
Redundancy	27.1 (26.9)	20.6 (21.2)	28.2 (26.2)	16.3 (14.3)
Structure determination Refinement				
Resolution cut-off (Å)	34.50- 3.25	45.80- 3.10	20.00- 3.32	25.00- 3.71
No. of Work / Test reflections	9888/474	10725/528	9251/445	6860/684
R_{cryst} (%) / R_{free} (%)	216/23.5	21.7/25.9	20.9/25.3	22.7/25.4
No. of protein atoms	3008	2960	2995	3008
No. of heteroatoms	42	42	10	62
B factors (Å) ²				
Protein	126.2	111.8	137.0	135.5
Heteroatoms	123.5	99.5	125.6	132.7
R.m.s. deviations from ideal				
Bond lengths (Å)	0.009	0.01	0.009	0.009
Bond angles (°)	1.06	1.12	1.05	1.03

One crystal was used to collect diffraction datasets for each structure, except in the EAAT1_{cryst} UCPH101 and TFB-TBOA bound structure, where datasets from three crystals were merged.

5% of reflections were used for calculations of R_{free} , except for the EAAT1_{cryst} UCPH101-TBOATFB bound structure where 10% was used due to the lower number of total reflections.

* Values in parentheses are for the highest-resolution shell.

§ The anisotropy directions were computed with AIMLESS.

Acknowledgements

We thank Olga Boudker for comments on the manuscript and discussion on consensus mutagenesis; Petya V. Krasteva for comments on the manuscript; Ahmed Haouz and the staff at the crystallography core facility of the Institut Pasteur for assistance with crystallization screens; Staff at Synchrotron Soleil and the European Synchrotron Radiation Facility for assistance with data collection; Darragh O'Brien for discussion of HDX results. The work was funded by the ERC Starting grant 309657 (N.R.). Further support from G5 Institut Pasteur funds (N.R.), CACSICE grant (ANR-11-EQPX-008), and CNRS UMR3528 (N.R., J.C.-R.) is acknowledged.

References

1. Slotboom DJ, Konings WN, Lolkema JS. Structural features of the glutamate transporter family. *Microbiol Mol Biol Rev.* 1999; 63:293–307. [PubMed: 10357852]
2. Kanai Y, Hediger MA. The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. *Eur J Pharmacol.* 2003; 479:237–247. [PubMed: 14612154]
3. Danbolt NC. Glutamate uptake. *Prog Neurobiol.* 2001; 65:1–105. [PubMed: 11369436]
4. Lehre KP, Danbolt NC. The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. *J Neurosci.* 1998; 18:8751–8757. [PubMed: 9786982]
5. Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter. *Nature.* 1996; 383:634–637. DOI: 10.1038/383634a0 [PubMed: 8857541]
6. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. *Ann Neurol.* 1995; 38:73–84. DOI: 10.1002/ana.410380114 [PubMed: 7611729]

7. Winter N, Kovermann P, Fahlke C. A point mutation associated with episodic ataxia 6 increases glutamate transporter anion currents. *Brain*. 2012; 135:3416–3425. DOI: 10.1093/brain/aws255 [PubMed: 23107647]
8. Choi KD, et al. Late-onset episodic ataxia associated with SLC1A3 mutation. *J Hum Genet*. 2016; doi: 10.1038/jhg.2016.137
9. Chao XD, Fei F, Fei Z. The role of excitatory amino acid transporters in cerebral ischemia. *Neurochem Res*. 2010; 35:1224–1230. DOI: 10.1007/s11064-010-0178-3 [PubMed: 20440555]
10. Pilc A, Wieronska JM, Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. *Biol Psychiatry*. 2013; 73:1125–1132. DOI: 10.1016/j.biopsych.2013.01.021 [PubMed: 23453290]
11. Robert SM, Sontheimer H. Glutamate transporters in the biology of malignant gliomas. *Cell Mol Life Sci*. 2014; 71:1839–1854. DOI: 10.1007/s00018-013-1521-z [PubMed: 24281762]
12. Zerangue N, Kavanaugh MP. ASCT-1 is a neutral amino acid exchanger with chloride channel activity. *J Biol Chem*. 1996; 271:27991–27994. [PubMed: 8910405]
13. Wang Q, et al. Targeting glutamine transport to suppress melanoma cell growth. *Int J Cancer*. 2014; 135:1060–1071. DOI: 10.1002/ijc.28749 [PubMed: 24531984]
14. Shimizu K, et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. *Br J Cancer*. 2014; 110:2030–2039. DOI: 10.1038/bjc.2014.88 [PubMed: 24603303]
15. Wang Q, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *J Pathol*. 2015; 236:278–289. DOI: 10.1002/path.4518 [PubMed: 25693838]
16. van Geldermalsen M, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. *Oncogene*. 2016; 35:3201–3208. DOI: 10.1038/onc.2015.381 [PubMed: 26455325]
17. Shimamoto K. Glutamate transporter blockers for elucidation of the function of excitatory neurotransmission systems. *Chem Rec*. 2008; 8:182–199. DOI: 10.1002/tcr.20145 [PubMed: 18563834]
18. Grewer C, Grabsch E. New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na⁺-dependent anion leak. *J Physiol*. 2004; 557:747–759. DOI: 10.1113/jphysiol.2004.062521 [PubMed: 15107471]
19. Jensen AA, et al. Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1. *J Med Chem*. 2009; 52:912–915. DOI: 10.1021/jm8013458 [PubMed: 19161278]
20. Abrahamsen B, et al. Allosteric modulation of an excitatory amino acid transporter: the subtype-selective inhibitor UCPH-101 exerts sustained inhibition of EAAT1 through an intramonomeric site in the trimerization domain. *J Neurosci*. 2013; 33:1068–1087. DOI: 10.1523/JNEUROSCI.3396-12.2013 [PubMed: 23325245]
21. Yernool D, Boudker O, Jin Y, Gouaux E. Structure of a glutamate transporter homologue from *Pyrococcus horikoshii*. *Nature*. 2004; 431:811–818. DOI: 10.1038/nature03018 [PubMed: 15483603]
22. Reyes N, Ginter C, Boudker O. Transport mechanism of a bacterial homologue of glutamate transporters. *Nature*. 2009; 462:880–885. DOI: 10.1038/nature08616 [PubMed: 19924125]
23. Akyuz N, et al. Transport domain unlocking sets the uptake rate of an aspartate transporter. *Nature*. 2015; 518:68–73. DOI: 10.1038/nature14158 [PubMed: 25652997]
24. Boudker O, Ryan RM, Yernool D, Shimamoto K, Gouaux E. Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. *Nature*. 2007; 445:387–393. DOI: 10.1038/nature05455 [PubMed: 17230192]
25. Zhang Y, Bendahan A, Zarbiv R, Kavanaugh MP, Kanner BI. Molecular determinant of ion selectivity of a (Na⁺ + K⁺)-coupled rat brain glutamate transporter. *Proc Natl Acad Sci U S A*. 1998; 95:751–755. [PubMed: 9435265]
26. Seal RP, Amara SG. A reentrant loop domain in the glutamate carrier EAAT1 participates in substrate binding and translocation. *Neuron*. 1998; 21:1487–1498. [PubMed: 9883740]
27. Tao Z, et al. Mechanism of cation binding to the glutamate transporter EAAC1 probed with mutation of the conserved amino acid residue Thr101. *J Biol Chem*. 2010; 285:17725–17733. DOI: 10.1074/jbc.M110.121798 [PubMed: 20378543]

28. Larsson HP, et al. Evidence for a third sodium-binding site in glutamate transporters suggests an ion/substrate coupling model. *Proc Natl Acad Sci U S A*. 2010; 107:13912–13917. DOI: 10.1073/pnas.1006289107 [PubMed: 20634426]
29. Guskov A, Jensen S, Faustino I, Marrink SJ, Slotboom DJ. Coupled binding mechanism of three sodium ions and aspartate in the glutamate transporter homologue GltTk. *Nat Commun*. 2016; 7:13420.doi: 10.1038/ncomms13420 [PubMed: 27830699]
30. Crisman TJ, Qu S, Kanner BI, Forrest LR. Inward-facing conformation of glutamate transporters as revealed by their inverted-topology structural repeats. *Proc Natl Acad Sci U S A*. 2009; 106:20752–20757. DOI: 10.1073/pnas.0908570106 [PubMed: 19926849]
31. Focke PJ, Moenne-Loccoz P, Larsson HP. Opposite movement of the external gate of a glutamate transporter homolog upon binding cotransported sodium compared with substrate. *J Neurosci*. 2011; 31:6255–6262. DOI: 10.1523/JNEUROSCI.6096-10.2011 [PubMed: 21508248]
32. Brocke L, Bendahan A, Grunewald M, Kanner BI. Proximity of two oppositely oriented reentrant loops in the glutamate transporter GLT-1 identified by paired cysteine mutagenesis. *J Biol Chem*. 2002; 277:3985–3992. DOI: 10.1074/jbc.M107735200 [PubMed: 11724778]
33. Qu S, Kanner BI. Substrates and non-transportable analogues induce structural rearrangements at the extracellular entrance of the glial glutamate transporter GLT-1/EAAT2. *J Biol Chem*. 2008; 283:26391–26400. DOI: 10.1074/jbc.M802401200 [PubMed: 18658151]
34. Seal RP, Leighton BH, Amara SG. A model for the topology of excitatory amino acid transporters determined by the extracellular accessibility of substituted cysteines. *Neuron*. 2000; 25:695–706. [PubMed: 10774736]
35. Grunewald M, Bendahan A, Kanner BI. Biotinylation of single cysteine mutants of the glutamate transporter GLT-1 from rat brain reveals its unusual topology. *Neuron*. 1998; 21:623–632. [PubMed: 9768848]
36. Ryan RM, Kortt NC, Sirivanta T, Vandenberg RJ. The position of an arginine residue influences substrate affinity and K⁺ coupling in the human glutamate transporter, EAAT1. *J Neurochem*. 2010; 114:565–575. DOI: 10.1111/j.1471-4159.2010.06796.x [PubMed: 20477940]
37. Borre L, Kanner BI. Arginine 445 controls the coupling between glutamate and cations in the neuronal transporter EAAC-1. *J Biol Chem*. 2004; 279:2513–2519. DOI: 10.1074/jbc.M311446200 [PubMed: 14594797]
38. Bailey CG, et al. Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. *J Clin Invest*. 2011; 121:446–453. DOI: 10.1172/JCI44474 [PubMed: 21123949]
39. Leinenweber A, Machtens JP, Begemann B, Fahlke C. Regulation of glial glutamate transporters by C-terminal domains. *J Biol Chem*. 2011; 286:1927–1937. DOI: 10.1074/jbc.M110.153486 [PubMed: 21097502]
40. Shouffani A, Kanner BI. Cholesterol is required for the reconstruction of the sodium- and chloride-coupled, gamma-aminobutyric acid transporter from rat brain. *J Biol Chem*. 1990; 265:6002–6008. [PubMed: 2318845]
41. Butchbach ME, Tian G, Guo H, Lin CL. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. *J Biol Chem*. 2004; 279:34388–34396. DOI: 10.1074/jbc.M403938200 [PubMed: 15187084]
42. McIlwain BC, Vandenberg RJ, Ryan RM. Transport rates of a glutamate transporter homologue are influenced by the lipid bilayer. *J Biol Chem*. 2015; 290:9780–9788. DOI: 10.1074/jbc.M114.630590 [PubMed: 25713135]
43. Fairman WA, Sonders MS, Murdoch GH, Amara SG. Arachidonic acid elicits a substrate-gated proton current associated with the glutamate transporter EAAT4. *Nat Neurosci*. 1998; 1:105–113. DOI: 10.1038/355 [PubMed: 10195124]
44. Raunser S, et al. Heterologously expressed GLT-1 associates in approximately 200-nm protein-lipid islands. *Biophys J*. 2006; 91:3718–3726. DOI: 10.1529/biophysj.106.086900 [PubMed: 16950847]
45. Wales TE, Engen JR. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. *Mass Spectrom Rev*. 2006; 25:158–170. DOI: 10.1002/mas.20064 [PubMed: 16208684]

46. Konermann L, Pan J, Liu YH. Hydrogen exchange mass spectrometry for studying protein structure and dynamics. *Chem Soc Rev.* 2011; 40:1224–1234. DOI: 10.1039/c0cs00113a [PubMed: 21173980]
47. Shimamoto K, et al. Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters. *Mol Pharmacol.* 2004; 65:1008–1015. DOI: 10.1124/mol.65.4.1008 [PubMed: 15044631]
48. Watzke N, Grewer C. The anion conductance of the glutamate transporter EAAC1 depends on the direction of glutamate transport. *FEBS Lett.* 2001; 503:121–125. [PubMed: 11513867]
49. Reyes N, Oh S, Boudker O. Binding thermodynamics of a glutamate transporter homolog. *Nat Struct Mol Biol.* 2013; 20:634–640. DOI: 10.1038/nsmb.2548 [PubMed: 23563139]
50. Kawate T, Gouaux E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. *Structure.* 2006; 14:673–681. DOI: 10.1016/j.str.2006.01.013 [PubMed: 16615909]
51. Steipe B, Schiller B, Pluckthun A, Steinbacher S. Sequence statistics reliably predict stabilizing mutations in a protein domain. *J Mol Biol.* 1994; 240:188–192. DOI: 10.1006/jmbi.1994.1434 [PubMed: 8028003]
52. Kabsch W. Xds. *Acta Crystallogr D Biol Crystallogr.* 2010; 66:125–132. DOI: 10.1107/S0907444909047337 [PubMed: 20124692]
53. Evans PR, Murshudov GN. How good are my data and what is the resolution? *Acta Crystallogr D Biol Crystallogr.* 2013; 69:1204–1214. DOI: 10.1107/S0907444913000061 [PubMed: 23793146]
54. McCoy AJ, et al. Phaser crystallographic software. *J Appl Crystallogr.* 2007; 40:658–674. DOI: 10.1107/S0021889807021206 [PubMed: 19461840]
55. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr.* 2010; 66:486–501. DOI: 10.1107/S0907444910007493 [PubMed: 20383002]
56. Blanc E, et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. *Acta Crystallogr D Biol Crystallogr.* 2004; 60:2210–2221. DOI: 10.1107/S0907444904016427 [PubMed: 15572774]
57. O'Brien DP, et al. Structural models of intrinsically disordered and calcium-bound folded states of a protein adapted for secretion. *Sci Rep.* 2015; 5:14223. doi: 10.1038/srep14223 [PubMed: 26374675]
58. Hourdel V, et al. MEMHDX: An interactive tool to expedite the statistical validation and visualization of large HDX-MS datasets. *Bioinformatics.* 2016; doi: 10.1093/bioinformatics/btw420
59. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics.* 2009; 25:1189–1191. DOI: 10.1093/bioinformatics/btp033 [PubMed: 19151095]




Figure 1. Function and architecture of EAAT1_{cryst}.

a-b, Uptake of radioactive L-glutamate by purified EAAT1 (grey), EAAT1_{cryst} (blue), and EAAT1_{cryst-II} (red) reconstituted in liposomes. Transport was abolished when choline (Ch⁺) was used in the extra- or intra-liposomal solutions (yellow circles) (**a**). UCPH₁₀₁ inhibits glutamate transport in a concentration dependent manner (**b**). Plots depict an average of three independent experiments performed with duplicate measurements, and error bars represent s.e.m. **c-d**, Structure of EAAT1_{cryst} trimer viewed from the extracellular solution (**c**) and from the membrane (**d**) highlighting the ScaD (teal) and TranD (orange). **e**,

EAAT1_{cryst} monomer viewed parallel to the membrane. The ScaD domain is represented as surface (teal), and several helices and loops in the TranD (orange) have been removed. **f**, Domain organization diagram of EAAT1_{cryst} monomer.




Figure 2. Transport domain.

EAAT1_{cryst} TranD with substrate (spheres) and one sodium ion (purple spheres) bound.

Omit Fo-Fc densities contoured at 2.3σ (black mesh) show the position of the ligands.

TM8a-c (blue) interacts with other regions on the TranD (orange), including HP1 (left inset),

HP2 (upper right inset), and TM3 and TM7 (lower right inset).




Figure 3. Scaffold domain.

a, TM4 (purple) makes extensive contacts with the ScaD of the neighboring monomer (monomer 2, teal surface), and the TranD (orange) of the same subunit (monomer 1). The TranD of monomer 2, and several TMs of monomer 1 were removed for clarity of display. Fo-Fc density in the HP2-TM4 crevice is contoured at 2.7σ (red mesh). **b**, Two monomers of EAAT_{cryst} show TM1a laying parallel to the membrane. The third monomer is not shown. TM1 (teal) and HP1a (dark blue) form a hydrophobic crevice containing non-protein Fo-Fc density (purple mesh, contour 2.7σ).




Figure 4. UCPH₁₀₁ binding site.

a, Lateral view of EAAT1_{cryst} monomer showing UCPH₁₀₁ bound (pink) between the TranD (orange) and ScaD (teal). **b-c**, UCPH₁₀₁ coordination and Fo-Fc densities contoured at 2.0 σ (blue mesh) in EAAT1_{cryst} (**b**) and EAAT1_{cryst-II} (**c**), respectively. Side chains of residues in TM3, TM4c, and TM7 involved in coordination are shown. F369 side chain moves outward in the EAAT1_{cryst-II} unbound state (grey) (**c**).




Figure 5. Transport domain dynamics.

a, UCPH₁₀₁ decreased deuterium uptake in several regions (black) of the TranD at the interface with the ScaD. The alpha carbon atoms delimiting such regions are shown as black spheres. Unaffected regions of the TranD (orange) or those not detected during HDX-MS analysis (grey) are also highlighted (sequence coverage $\sim 77\%$). **b**, TranD residues buried at the interface with the ScaD, in the UCPH₁₀₁-bound outward-facing state, are colored dark blue for comparison with **(a)**. **c-d**, Comparison between EAAT1_{cryst} structure in the UCPH₁₀₁-bound outward-facing state **(c)** and a model of an inward-facing state based on the GltPh “unlocked” state (PDB 4X2S) **(d)**, in which the TranD (color code as in **a**) undergoes a large rigid body movement towards the cytoplasm.




Figure 6. UCPH₁₀₁-TBOA_{TFB} bound EAAT1_{cryst} structure.

a, The movement of HP2 (purple) partly exposes the substrate-binding pocket to the solvent and shows a molecule of TBOA_{TFB} (purple sticks) bound to it. UCPH₁₀₁ is also observed in this structure (pink sticks). **b**, The tip of HP2 moves as much as 9.5 Å in the UCPH₁₀₁-TBOA_{TFB}- (purple), compared to the UCPH₁₀₁-substrate bound (orange) structures, placing the carbonyl oxygen of A420 away from Na₂ (green sphere). **c**, Omit map Fo-Fc density for the TBOA_{TFB} molecule is contoured at 2.3σ (black mesh), and some of the residues at Van der Waals or H-bond distance from the compound are represented as sticks.




Figure 7. EAAT1 inhibitory mechanisms.

Schematic representation of TBOA-like competitive and UCPH₁₀₁-like allosteric inhibition. Competitive inhibitors, occupy the substrate-binding pocket and preclude substrate binding. UCPH₁₀₁-like compounds bind at the TranD-ScaD interface and block the movement of the TranD (orange) relative to the ScaD (teal).